Renal function in gout: long-term treatment effects of febuxostatAndrew Whelton
Universal Clinical Research Center, Inc, 1737 Beaver Brook Lane, Hunt Valley, MD 21030 1603, USA
J Clin Rheumatol 17:7-13. 2011
..In healthy adults, glomerular filtration rate wanes with age. Urate-lowering therapy (ULT) with allopurinol has been shown to stabilize or reverse this...
Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofenA Whelton
The Universal Clinical Research Center Inc, Hunt Valley, Maryland 21030 1603, USA
Kidney Int 70:1495-502. 2006
..3%; P < 0.05) and ibuprofen (7.3%; P < 0.05). A supratherapeutic dose of celecoxib was associated with an improved cardiorenal safety profile compared with standard doses of either ibuprofen or diclofenac...
- Preservation of renal function during gout treatment with febuxostat: a quantitative study
Andrew Whelton
Universal Clinical Research Center, Inc, Hunt Valley, MD The Johns Hopkins University School of Medicine, Baltimore, MD
Postgrad Med 125:106-14. 2013
..The results discussed in this article support similar observations previously reported in 116 hyperuricemic subjects with gout who received febuxostat for ≤ 5 years...
- Current and future therapeutic options for the management of gout
Andrew Whelton
Universal Clinical Research Center, Inc, Hunt Valley, MD, USA
Am J Ther 17:402-17. 2010
..This manuscript reviews the pathophysiology of hyperuricemia and gout, and associated comorbidities, and then discusses traditional therapeutic options, newly available agents, and future targets for pharmacologic management...
- Clinical implications of nonopioid analgesia for relief of mild-to-moderate pain in patients with or at risk for cardiovascular disease
Andrew Whelton
The Universal Clinical Research Center, Inc, Hunt Valley, Maryland, USA
Am J Cardiol 97:3-9. 2006
....
- Effects of celecoxib and naproxen on renal function in the elderly
A Whelton
Universal Clinical Research Center, Inc, Hunt Valley, MD 21030 1603, USA
Arch Intern Med 160:1465-70. 2000
..To compare the effects of celecoxib, a cyclooxygenase 2-specific inhibitor, with the nonspecific cyclooxygenase 1 and 2 inhibitor naproxen on renal function in 29 healthy elderly subjects in a single-blind, randomized, crossover study...
- COX-2-specific inhibitors and the kidney: effect on hypertension and oedema
Andrew Whelton
Universal Clinical Research Center, Inc, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Hypertens Suppl 20:S31-5. 2002
..4% compared with 0.1% in the naproxen group, P < 0.05). In summary, celecoxib may have safety and tolerability advantages compared with non-selective NSAIDs studied and may have some cardiorenal benefits compared with rofecoxib...
- Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics
A Whelton
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Am J Ther 7:63-74. 2000
..It is important that healthcare providers and practitioners are aware of the relative renal risks of different analgesics and that they use this knowledge to counsel the analgesic-consuming population appropriately...
- Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis
Andrew Whelton
Universal Clinical Research Center, Inc, and The Johns Hopkins University School of Medicine, Baltimore, Maryland 21030 1603, USA
Am J Cardiol 90:959-63. 2002
..7%) compared with the celecoxib group (4.7%) (p <0.05). Thus, in patients with controlled hypertension on a fixed antihypertensive regimen, careful monitoring of BP is warranted after the initiation of celecoxib or rofecoxib therapy...
- Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis
William B White
Division of Hypertension and Clinical Pharmacology, Department of Medicine, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030 3940, USA
Am J Ther 11:244-50. 2004
....
- Minimizing cardiovascular complications during the treatment of osteoarthritis
Andrew Whelton
Universal Clinical Research Center, Inc, Baltimore, MD, USA
Am J Ther 18:466-76. 2011
....
- Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial
Arnold B Alper
Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
Am J Ther 13:229-35. 2006
..Thus, in this short-term study of human subjects, therapeutic doses of celecoxib did not appear to have a clinically significant inhibitory action on renal carbonic anhydrase...
- The coxib conundrum: lessons from the rise and fall of rofecoxib
Andrew Whelton
Am J Ther 11:417-21. 2004
- Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors
Sean Z Zhao
Pharmacia Corporation, Peapack, New Jersey, USA
Am J Manag Care 8:S401-13. 2002
....
- Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors
Sean Z Zhao
Pharmacia Corporation, Peapack, New Jersey, USA
Am J Manag Care 8:S414-27. 2002
..The higher heart failure costs of rofecoxib were attributable to the higher incidence of patients with inpatient and outpatient heart failure claims relative to celecoxib and nonspecific NSAID populations being compared...
- Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac
William B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
Am J Cardiol 89:425-30. 2002
....
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxibBarbara K Martin
Arch Neurol 65:896-905. 2008
..CONCLUSIONS: Use of naproxen or celecoxib did not improve cognitive function. There was weak evidence for a detrimental effect of naproxen...
- Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs
William M Spalding
Pfizer Inc, New York, NY, USA
Am J Ther 14:3-12. 2007
..That this effect was specific to hypertensive patients indicates that blood pressure destabilization is likely an important contributing mechanism...
- Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors
William B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
Hypertension 39:929-34. 2002
..The placebo-subtracted changes observed in 24-hour BP (1.6/1.2 mm Hg) are less than what has been reported for nonselective nonsteroidal anti-inflammatory agents in ACE inhibitor-treated patients...
- Controversies in COX-2 selective inhibition
Lee S Simon
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Rheumatol 29:1501-10. 2002
- Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension
Jane T Osterhaus
Wasatch Health Outcomes, Park City, Utah 84060, USA
Clin Ther 24:969-89. 2002
..The addition of a nonsteroidal anti-inflammatory drug to the regimen of a patient with treated hypertension can cause a destabilization of blood pressure...
- The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus
James R Sowers
State University of New York, Brooklyn, USA
Arch Intern Med 165:161-8. 2005
..However, destabilization of hypertension control occurred to some extent in all 3 treatment groups; this phenomenon was seen more often in patients treated with rofecoxib than with the other therapies...
- Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice
Sean Z Zhao
Pharmacia Corporation, Peapack, New Jersey, USA
Am J Manag Care 8:S392-400. 2002
....
